Pfizer: Analysts' New Targets, Estimates
Click here for Analysts' Upgrades, Downgrades.
Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
) --
STOCK COMMENTS / EPS CHANGES
AmerisourceBergen
(ABC) - Get Report
estimates, target raised at Oppenheimer. Shares of ABC now seen reaching $37, according to Oppenheimer. Estimates also increased, as the company should benefit from a strong generics pipeline. Outperform rating.
Agco
(AGCO) - Get Report
estimates, target raised at UBS. Shares of AGCO now seen reaching $41. Estimates also increased, to match the company's new guidance. Sell rating.
American Superconductor
(AMSC) - Get Report
numbers increased at Jefferies through 2011. Company boosted its guidance. Buy rating and new $42 price target.
Anadarko Petroleum
(APC) - Get Report
price target increased at Barclays to $71 from $66. Strong operating results in third-quarter, Barclays said. 2010 and 2011 EPS estimates reduced to $1.55 and $0.80, respectively. Maintain Overweight rating.
Carefusion
(CFN)
estimates, target lowered at Goldman. CFN estimates were cut through 2013. Company is seeing lower demand for respiratory care and infusion pumps. Buy rating and new $28 price target.
Clorox
(CLX) - Get Report
estimates, target reduced at Oppenheimer. Shares of CLX now seen reaching $70, according to Oppenheimer. Estimates also cut, because of lower domestic sales. Outperform rating.
Corinthian Colleges
(COCO)
price target cut at Barclays. COCO price target trimmed to $5 from $7 as significant challenges remain. Maintain Equal Weight rating.
Cooper Tire
(CTB) - Get Report
numbers increased at Morgan Stanley. CTB estimates were raised through 2011, Morgan Stanley said. Company is realizing higher margins, aided by increased efficiencies. Overweight rating and new $26 price target.
Dean Foods
(DF) - Get Report
numbers raised at Goldman. Shares of DF now seen reaching $11. Estimates also increased, given lower corporate costs. Neutral rating.
Consolidated Edison
(ED) - Get Report
numbers raised at Oppenheimer. Shares of ED now seen reaching $49, according to Oppenheimer. Estimates also increased, given lower debt costs. Perform rating.
Emerson Electric
(EMR) - Get Report
numbers boosted at Citigroup. Shares of EMR now seen reaching $54. Estimates also upped, given better organic growth. Hold rating.
EOG Resources
(EOG) - Get Report
estimates lowered at Morgan Stanley through 2012. Company reduced its production guidance. Equal-weight rating.
Kellogg
(K) - Get Report
estimate mixed at Barclays. K 2010 EPS estimate raised slightly to $3.27, 2011 cut to $3.44. Cautious guidance, Barclays noted. Maintain Neutral rating and $56 price target.
Kellogg
(K) - Get Report
estimates lowered at Goldman through 2011. Company is seeing softer sales. Neutral rating and $51 price target.
MasterCard
(MA) - Get Report
target, estimates boosted at Barclays. MA price target increased to $305 from $272. Company at compelling infection point on deconversions, Barclays said. 2010 and 2011 EPS estimates lifted to $13.96 and $17, respectively.
MasterCard
(MA) - Get Report
estimates, target upped at Goldman. MA estimates were boosted through 2012. Company is seeing higher global volume growth. Buy rating and new $285 price target.
Medco Health Solutions
(MHS)
estimate raised at Barclays. MHS 2011 EPS estimate increased to $4.07, 2010 maintained at $3.40. Reiterate Overweight rating and $69 price target.
Medco Health
(MHS)
numbers increased at Goldman. MHS estimates were raised through 2013, Goldman Sachs said. Company is seeing a greater generic benefit. Buy rating and new $68 price target.
Myriad Genetics
(MYGN) - Get Report
estimates upped at Morgan Stanley through 2013. Company is benefiting from improved utilization. Equal-weight rating.
NYSE Euronext
(NYX)
numbers cut at UBS. NYX estimates were lowered through 2011. Company is guiding to higher costs and not buying back as many shares. Buy rating and new $38 price target.
NYSE Euronext
(NYX)
numbers increased at Goldman. NYX estimates were raised through 2012. Company is seeing better tech revenue and paying lower taxes. Neutral rating and new $33 price target.
OpenTable
(OPEN)
estimates boosted at Morgan Stanley through 2012. Company's continues to post accelerated growth. Equal-weight rating.
Pfizer
(PFE) - Get Report
estimates upped at UBS through 2011, UBS said. Company is benefiting from currency rates. Buy rating and $21 price target.
Principal Financial
(PFG) - Get Report
estimates upped at Goldman through 2012. Company is likely to repurchase shares. Buy rating and $31 price target.
Perrigo
(PRGO) - Get Report
estimates, target boosted at Goldman. Shares of PRGO now seen reaching $52. Estimates also upped, as higher sales is driving margin growth. Sell rating.
Regal Entertainment
(RGC)
estimates upped at Morgan Stanley through 2012. Cost-cutting is offsetting lower sales. Underweight rating and $13 price target.
SM Energy
(SM) - Get Report
estimates, target boosted at UBS. Shares of SM now seen reaching $43, according to UBS. Estimates also upped, given better liquids demand. Neutral rating.
Tenet Healthcare
(THC) - Get Report
numbers lowered at Goldman. THC estimates were cut through 2012. Company is seeing lower hospital admissions. Neutral rating and new $5 price target.
Trimble Navigation
(TRMB) - Get Report
numbers boosted at Oppenheimer. Shares of TRMB now seen reaching $43. Estimates also upped, as the company is seeing better demand from agriculture and construction customers. Outperform rating.
Vishay
(VSH) - Get Report
estimates, target raised at Citigroup. Shares of VSH now seen reaching $15. Estimates also increased, given higher realized margins. Hold rating.
This article was written by a staff member of TheStreet.
